1.65Open1.65Pre Close0 Volume29 Open Interest25.00Strike Price0.00Turnover115.02%IV-15.02%PremiumDec 20, 2024Expiry Date4.70Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6931Delta0.0559Gamma3.56Leverage Ratio-0.0396Theta-0.0122Rho-2.47Eff Leverage0.0193Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet